Quest Diagnostics Reports First Quarter 2022 Financial Results; Raises Guidance for Full Year 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
CFRA Downgrades Quest Diagnostics (DGX) to Hold
April 21, 2022 1:53 PM EDTCFRA downgraded Quest Diagnostics (NYSE: DGX) from Buy to Hold with a price target of $157.00 (from $160.00).
For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $138.45 yesterday.
... MoreQuest Diagnostics (DGX) Tops Q1 EPS by 25c, Raises FY EPS Guidance
April 21, 2022 6:46 AM EDTQuest Diagnostics (NYSE: DGX) reported Q1 EPS of $3.22, $0.25 better than the analyst estimate of $2.97. Revenue for the quarter came in at $2.61 billion versus the consensus estimate of $2.63 billion.
GUIDANCE:
Quest Diagnostics sees FY2022 EPS of $9.00-$9.50, versus the consensus of... More
